Analyzing Female Health (VERU) and Carlisle Companies (CSL)

Female Health (NASDAQ: VERU) and Carlisle Companies (NYSE:CSL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a breakdown of current ratings and recommmendations for Female Health and Carlisle Companies, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Female Health 0 0 2 0 3.00
Carlisle Companies 0 2 6 0 2.75

Female Health currently has a consensus price target of $5.00, suggesting a potential upside of 177.78%. Carlisle Companies has a consensus price target of $122.86, suggesting a potential upside of 19.67%. Given Female Health’s stronger consensus rating and higher probable upside, research analysts plainly believe Female Health is more favorable than Carlisle Companies.

Insider and Institutional Ownership

4.1% of Female Health shares are owned by institutional investors. Comparatively, 88.0% of Carlisle Companies shares are owned by institutional investors. 37.0% of Female Health shares are owned by insiders. Comparatively, 2.4% of Carlisle Companies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Female Health and Carlisle Companies’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Female Health $13.66 million 7.05 -$6.61 million ($0.25) -7.20
Carlisle Companies $4.09 billion 1.55 $365.50 million $5.53 18.56

Carlisle Companies has higher revenue and earnings than Female Health. Female Health is trading at a lower price-to-earnings ratio than Carlisle Companies, indicating that it is currently the more affordable of the two stocks.


Carlisle Companies pays an annual dividend of $1.48 per share and has a dividend yield of 1.4%. Female Health does not pay a dividend. Carlisle Companies pays out 26.8% of its earnings in the form of a dividend. Carlisle Companies has increased its dividend for 41 consecutive years.

Volatility & Risk

Female Health has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Carlisle Companies has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.


This table compares Female Health and Carlisle Companies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Female Health -73.11% -17.63% -12.73%
Carlisle Companies 8.94% 13.53% 7.52%


Carlisle Companies beats Female Health on 12 of the 17 factors compared between the two stocks.

About Female Health

Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.

About Carlisle Companies

Carlisle Companies Incorporated operates as a diversified manufacturing company. The company's Carlisle Construction Materials segment provides insulation materials; thermoplastic polyolefin, ehtylene propylene diene monomer rubber, and polyvinyl chloride roofing membranes that are used on non-residential low-sloped roofs; roofing accessories, such as flashings, fasteners, sealing tapes, coatings, and waterproofing products; rigid foam insulation panels for roofing applications; and specialty polyurethane products and solutions for various markets and applications. Its Carlisle Interconnect Technologies segment designs, manufactures, and sells wires, cables, connectors, contacts, and cable assemblies and satellite communication equipment to transfer power and data for the aerospace, medical, defense electronics, test and measurement equipment, and other industrial markets. The company's Carlisle FoodService Products segment offers commercial and institutional foodservice permanentware, table coverings, cookware, catering equipment, fiberglass and composite material trays and dishes, industrial brooms, brushes, mops, and rotary brushes for commercial and non-commercial foodservice operators, and sanitary maintenance professionals. Its Carlisle Fluid Technologies segment provides liquid and powder finishing equipment and system components primarily in the automotive, automotive refinishing, aerospace, agriculture, construction, marine, and rail industries. The company's Carlisle Brake & Friction segment offers braking products and systems, and clutch transmission friction products for off-highway, on-highway, aircraft, and other industrial applications; and motorsport braking products. The company markets its products in the United States, Europe, Asia, Canada, Mexico, Latin America, the Middle East, Africa, and internationally. Carlisle Companies Incorporated was founded in 1917 and is headquartered in Scottsdale, Arizona.

Receive News & Ratings for Female Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Female Health and related companies with's FREE daily email newsletter.

Leave a Reply